VBIO — Valion Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787740 ·
Last close
$0.54
Market Cap
$482.3K
52W High
$67.50
52W Low
$0.47
ADV30
1,215,016
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,424,000 | -7,103,000 | 32,473,000 | 2,108,000 | 28,227,000 |
| Mar 2026 | 0 | — | -5,634,000 | -6,202,000 | 38,215,000 | 7,215,000 | 27,153,000 |
| Dec 2025 | -302,000 | — | -1,975,000 | -2,849,000 | 31,607,000 | 12,645,000 | 14,810,000 |
| Sep 2025 | 146,000 | -145,000 | -2,483,000 | -2,596,000 | 6,229,000 | 3,450,000 | 638,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,155,000
Investing CF
$-223,000
Financing CF
$16,090,000
CapEx
$-99,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-214.00
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-66,506,000
Inventory
$750,000
Receivables
$19,000
ST Investments
—
EBIT TTM
$-16,350,000
Pretax Income TTM
$-17,842,000
Interest Exp TTM
$1,339,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$-86,000
EBITDA
$-16,536,000
Free Cash Flow
$-8,062,250
Enterprise Value
$17,306,954
Total Cash
$2,108,000
Total Debt
$17,409,000
Shares Out
887,589
Trailing EPS
$-184.45
Book Value
$1.02
ROE
-459.5%
ROA
-57.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,898,000 | -8,878,000 | 31,607,000 | 14,810,000 | 16,797,000 | -6,999,000 |
| Dec 2024 | 0 | -4,476,000 | -5,655,000 | 2,810,000 | 272,000 | 2,535,000 | -5,725,000 |
| Dec 2023 | 1,176,000 | -8,245,000 | -8,244,000 | 5,160,000 | 1,577,000 | 3,580,000 | -8,511,000 |
| Dec 2022 | 1,840,000 | -10,098,000 | -10,096,000 | 5,880,000 | 2,245,000 | 3,630,000 | -8,919,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-98,000
NetIncome TTM
$-18,750,000
OpCashFlow TTM
—
Assets (Latest)
$32,473,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $508.3K | $0.21 | — |
| EVFM | Evofem Biosciences, Inc. | $569.9K | $0.00 | — |
| CYTOF | Altamira Therapeutics Ltd. | $405.8K | $0.07 | — |
| BIOM | BIOMOLECULAR LIFE HOLDINGS, INC. | $580.8K | $0.50 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $814.6K | $0.45 | — |
News headlines (Yahoo Finance, 1h cache)
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
2026-11-17 13:05 · Yahoo
Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
2026-11-11 13:10 · Yahoo
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
2026-10-30 12:50 · Yahoo
Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
2026-10-28 11:45 · Yahoo
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
2026-10-26 12:00 · Yahoo
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
2026-10-21 12:00 · Yahoo
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
2026-10-15 12:00 · Yahoo
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
2026-10-14 12:15 · Yahoo
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand
2026-10-09 11:45 · Yahoo
Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development Pathway
2026-09-30 14:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.